KU ASH 2018 Review: Current Updates in Hematologic Diseases
Avatar

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT

By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Elihu H. Estey
By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Elihu H. Estey
0 views
March 19, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Playlist AML - Keynote - Latest updates on Standard Therapies and Investigational Therapies, MRD in AML, HTC and Non-HCT

23:37
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies…

Feat. E. Estey
05:54
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Re…

Feat. E. Estey
06:26
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantat…

Feat. E. Estey
14:49
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML Challenges in Evaluating New Therapies: Understanding t…

Feat. E. Estey
Thumbs Up
  • March 19, 2019

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
14:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…

Feat. C. McMahon
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
48:04
Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

Feat. H. Kantarjian
28:02
University of Colorado Division of Hematology

2024 Updates in AML

Feat. C. McMahon
27:26
SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

Feat. J. Lancet
27:28
UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis
14:19
Talha Badar

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

09:42
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…

Feat. M. Al Malki
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
12:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian